PLoS ONE, ISSN 1932-6203, 08/2016, Volume 11, Issue 8, pp. e0161562 - e0161562
Background In resource-limited settings, routine monitoring of renal function during antiretroviral therapy (ART) has not been recommended. However, concerns...
BASE-LINE | RISK-FACTORS | MULTIDISCIPLINARY SCIENCES | DISOPROXIL FUMARATE | INCOMPLETE REVERSIBILITY | ANTIRETROVIRAL THERAPY | DEATH | CHRONIC KIDNEY-DISEASE | ASSOCIATION | EXPOSURE | DECLINE | Glomerular Filtration Rate | Kidney - drug effects | Prospective Studies | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Male | Kidney Diseases - chemically induced | Creatinine - blood | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Poisson Distribution | Kidney - physiopathology | Databases, Factual | Tenofovir | Complications and side effects | Chronic kidney failure | Patient outcomes | Dosage and administration | Research | Drug therapy | HIV infection | Risk factors | Health sciences | Renal function | Epidemiology | Incidence | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Blood pressure | Poisson density functions | Monitoring | Chronic illnesses | Creatinine | Hypertension | Antiretroviral drugs | Statistical analysis | Epidermal growth factor receptors | Mortality | Risk analysis | Patients | Antiretroviral therapy | Glomerular filtration rate | Medicine | Infectious diseases | Hospitals | Kidney diseases | Index Medicus | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
BASE-LINE | RISK-FACTORS | MULTIDISCIPLINARY SCIENCES | DISOPROXIL FUMARATE | INCOMPLETE REVERSIBILITY | ANTIRETROVIRAL THERAPY | DEATH | CHRONIC KIDNEY-DISEASE | ASSOCIATION | EXPOSURE | DECLINE | Glomerular Filtration Rate | Kidney - drug effects | Prospective Studies | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Male | Kidney Diseases - chemically induced | Creatinine - blood | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Poisson Distribution | Kidney - physiopathology | Databases, Factual | Tenofovir | Complications and side effects | Chronic kidney failure | Patient outcomes | Dosage and administration | Research | Drug therapy | HIV infection | Risk factors | Health sciences | Renal function | Epidemiology | Incidence | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Blood pressure | Poisson density functions | Monitoring | Chronic illnesses | Creatinine | Hypertension | Antiretroviral drugs | Statistical analysis | Epidermal growth factor receptors | Mortality | Risk analysis | Patients | Antiretroviral therapy | Glomerular filtration rate | Medicine | Infectious diseases | Hospitals | Kidney diseases | Index Medicus | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2016, Volume 11, Issue 4, p. e0153243
World Health Organization advocates for integration of HIV-tuberculosis (TB) services and recommends intensive case finding (ICF), isoniazid preventive therapy...
South America | Poverty | World Health Organization | Humans | AIDS-Related Opportunistic Infections - drug therapy | Africa | Infection Control | AIDS-Related Opportunistic Infections - diagnosis | Caribbean Region | Tuberculosis - diagnosis | AIDS-Related Opportunistic Infections - prevention & control | Asia | Tuberculosis - drug therapy | Tuberculosis - prevention & control | HIV Infections - complications | HIV Infections - drug therapy | Isoniazid - therapeutic use | Antitubercular Agents - therapeutic use | Prevention | Complications and side effects | Usage | Tuberculosis | Dosage and administration | Research | Diagnosis | Drug therapy | Medicine, Preventive | Isoniazid | Preventive health services | Health care | Medical personnel | Therapy | Integration | Income | Infections | Tuberculin | Preventive medicine | Medical diagnosis | Patients | Masks | Studies | Screening | Acquired immune deficiency syndrome--AIDS | Workers | Collaboration | Human immunodeficiency virus--HIV | Smear | Occupational health | Skin | Skin tests | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
South America | Poverty | World Health Organization | Humans | AIDS-Related Opportunistic Infections - drug therapy | Africa | Infection Control | AIDS-Related Opportunistic Infections - diagnosis | Caribbean Region | Tuberculosis - diagnosis | AIDS-Related Opportunistic Infections - prevention & control | Asia | Tuberculosis - drug therapy | Tuberculosis - prevention & control | HIV Infections - complications | HIV Infections - drug therapy | Isoniazid - therapeutic use | Antitubercular Agents - therapeutic use | Prevention | Complications and side effects | Usage | Tuberculosis | Dosage and administration | Research | Diagnosis | Drug therapy | Medicine, Preventive | Isoniazid | Preventive health services | Health care | Medical personnel | Therapy | Integration | Income | Infections | Tuberculin | Preventive medicine | Medical diagnosis | Patients | Masks | Studies | Screening | Acquired immune deficiency syndrome--AIDS | Workers | Collaboration | Human immunodeficiency virus--HIV | Smear | Occupational health | Skin | Skin tests | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
3.
Full Text
Effects of unplanned treatment interruptions on HIV treatment failure – results from TAHOD
Tropical Medicine & International Health, ISSN 1360-2276, 05/2016, Volume 21, Issue 5, pp. 662 - 674
Objectives Treatment interruptions (TIs) of combination antiretroviral therapy (cART) are known to lead to unfavourable treatment outcomes but do still occur...
effets indésirables | adverse events | interrupción del tratamiento | eventos adversos | antiretroviral | Asie | HIV | VIH | treatment interruptions | Asia | interruptions de traitement | antirétroviral | antirretroviral | Antiretroviral | Adverse events | Treatment interruptions | TREATMENT OUTCOMES | IMMUNOLOGICAL RESPONSE | FOLLOW-UP | DRUG-RESISTANCE | REGIMENS | ADHERENCE | TROPICAL MEDICINE | POSITIVE INDIVIDUALS | OBSERVATIONAL DATABASE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | VIROLOGICAL FAILURE | ACTIVE ANTIRETROVIRAL THERAPY | Medication Adherence - statistics & numerical data | Medication Adherence - psychology | Prospective Studies | Drug Administration Schedule | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Male | Treatment Outcome | CD4 Lymphocyte Count | Disease Progression | Viral Load | Anti-HIV Agents - administration & dosage | Time Factors | Treatment Failure | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Antiviral agents | HIV (Viruses) | AIDS treatment | Analysis | Antiretroviral drugs | Human immunodeficiency virus--HIV | Medical treatment | Clinical outcomes
effets indésirables | adverse events | interrupción del tratamiento | eventos adversos | antiretroviral | Asie | HIV | VIH | treatment interruptions | Asia | interruptions de traitement | antirétroviral | antirretroviral | Antiretroviral | Adverse events | Treatment interruptions | TREATMENT OUTCOMES | IMMUNOLOGICAL RESPONSE | FOLLOW-UP | DRUG-RESISTANCE | REGIMENS | ADHERENCE | TROPICAL MEDICINE | POSITIVE INDIVIDUALS | OBSERVATIONAL DATABASE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | VIROLOGICAL FAILURE | ACTIVE ANTIRETROVIRAL THERAPY | Medication Adherence - statistics & numerical data | Medication Adherence - psychology | Prospective Studies | Drug Administration Schedule | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Male | Treatment Outcome | CD4 Lymphocyte Count | Disease Progression | Viral Load | Anti-HIV Agents - administration & dosage | Time Factors | Treatment Failure | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Antiviral agents | HIV (Viruses) | AIDS treatment | Analysis | Antiretroviral drugs | Human immunodeficiency virus--HIV | Medical treatment | Clinical outcomes
Journal Article
Journal of the International AIDS Society, ISSN 1758-2652, 01/2016, Volume 19, Issue 1, pp. 20965 - n/a
Introduction Outbreaks of syphilis have been described among HIV‐infected men who have sex with men (MSM) in Western communities, whereas reports in Asian...
syphilis | seroconversion | HIV | incidence | MSM | Seroconversion | Syphilis | Incidence | VIRAL LOAD | INFECTIOUS DISEASES | CD4 CELL COUNTS | IMMUNODEFICIENCY-VIRUS-INFECTION | TRANSMITTED INFECTIONS | ASYMPTOMATIC SYPHILIS | IMMUNOLOGY | SAN-FRANCISCO | HOMOSEXUAL-MEN | SEXUAL RISK BEHAVIOR | POSITIVE GAY MEN | CHANGING PATTERNS | HIV Infections - epidemiology | Humans | Middle Aged | Risk Factors | Male | Syphilis - epidemiology | Asia - epidemiology | Homosexuality, Male | Syphilis - diagnosis | Adolescent | HIV Infections - complications | Adult | Female | Syphilis - complications | Complications and side effects | Research | HIV infection | Analysis | Risk factors | Medicine | Hospitals | Disease transmission | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Infections | Data bases
syphilis | seroconversion | HIV | incidence | MSM | Seroconversion | Syphilis | Incidence | VIRAL LOAD | INFECTIOUS DISEASES | CD4 CELL COUNTS | IMMUNODEFICIENCY-VIRUS-INFECTION | TRANSMITTED INFECTIONS | ASYMPTOMATIC SYPHILIS | IMMUNOLOGY | SAN-FRANCISCO | HOMOSEXUAL-MEN | SEXUAL RISK BEHAVIOR | POSITIVE GAY MEN | CHANGING PATTERNS | HIV Infections - epidemiology | Humans | Middle Aged | Risk Factors | Male | Syphilis - epidemiology | Asia - epidemiology | Homosexuality, Male | Syphilis - diagnosis | Adolescent | HIV Infections - complications | Adult | Female | Syphilis - complications | Complications and side effects | Research | HIV infection | Analysis | Risk factors | Medicine | Hospitals | Disease transmission | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Infections | Data bases
Journal Article
Journal of Clinical Epidemiology, ISSN 0895-4356, 2016, Volume 76, pp. 183 - 192
Abstract Objectives In multisite human immunodeficiency virus (HIV) observational cohorts, clustering of observations often occurs within sites. Ignoring...
Internal Medicine | Simpson's paradox | Human immunodeficiency virus | Cohort | Clustering | Cox | Yule-Simpson | MORTALITY | PERFORMANCE | IMMUNOLOGICAL RESPONSE | ADULTS | ANTIRETROVIRAL THERAPY | DRUG-RESISTANCE | CHILDREN | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | PROGRAMS | VIROLOGICAL FAILURE | HEALTH CARE SCIENCES & SERVICES | Data Interpretation, Statistical | HIV Infections - epidemiology | Humans | Middle Aged | Proportional Hazards Models | Male | Mortality - trends | Forecasting | Asia - epidemiology | HIV Infections - diagnosis | Survival Analysis | Aged, 80 and over | Adult | Anti-HIV Agents - therapeutic use | Biomedical Research - methods | Female | HIV Infections - drug therapy | HIV Infections - mortality | Aged | Research Design | Cohort Studies | Databases, Factual | HIV (Viruses) | Databases | Studies | Confidence intervals | Antiretroviral drugs | Survival analysis | Hepatitis | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Mortality | Research | Drug therapy | Clinical outcomes | cohort | clustering | HIV
Internal Medicine | Simpson's paradox | Human immunodeficiency virus | Cohort | Clustering | Cox | Yule-Simpson | MORTALITY | PERFORMANCE | IMMUNOLOGICAL RESPONSE | ADULTS | ANTIRETROVIRAL THERAPY | DRUG-RESISTANCE | CHILDREN | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | PROGRAMS | VIROLOGICAL FAILURE | HEALTH CARE SCIENCES & SERVICES | Data Interpretation, Statistical | HIV Infections - epidemiology | Humans | Middle Aged | Proportional Hazards Models | Male | Mortality - trends | Forecasting | Asia - epidemiology | HIV Infections - diagnosis | Survival Analysis | Aged, 80 and over | Adult | Anti-HIV Agents - therapeutic use | Biomedical Research - methods | Female | HIV Infections - drug therapy | HIV Infections - mortality | Aged | Research Design | Cohort Studies | Databases, Factual | HIV (Viruses) | Databases | Studies | Confidence intervals | Antiretroviral drugs | Survival analysis | Hepatitis | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Mortality | Research | Drug therapy | Clinical outcomes | cohort | clustering | HIV
Journal Article
AIDS Research and Therapy, ISSN 1742-6405, 05/2017, Volume 14, Issue 1, pp. 27 - 8
Background: Abacavir and rilpivirine are alternative antiretroviral drugs for treatment-naive HIV-infected patients. However, both drugs are only recommended...
Model | HIV RNA | Rilpivirine | Abacavir | Prediction | INFECTIOUS DISEASES | ANTIRETROVIRAL THERAPY | HIV-1-INFECTED ADULTS | Prospective Studies | HIV Infections - virology | Humans | Decision Support Techniques | Male | RNA, Viral - blood | Viral Load | Rilpivirine - therapeutic use | Asia | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Developing Countries | Dideoxynucleosides - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Drugs | Derivation | Infections | Data bases | Variables | Body mass index | Databases | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Mathematical models | Teenagers | Pretreatment | Drug therapy | Drug dosages | Age | Antiretroviral drugs | Statistical analysis | Adjustment | Cut-off | Anemia | Data processing | Time measurement | Regression analysis | Ribonucleic acid--RNA | Patients | Antiretroviral therapy | CD4 antigen | Disease prevention | Sensitivity | Body mass | Cell number | Predictions | Adults
Model | HIV RNA | Rilpivirine | Abacavir | Prediction | INFECTIOUS DISEASES | ANTIRETROVIRAL THERAPY | HIV-1-INFECTED ADULTS | Prospective Studies | HIV Infections - virology | Humans | Decision Support Techniques | Male | RNA, Viral - blood | Viral Load | Rilpivirine - therapeutic use | Asia | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Developing Countries | Dideoxynucleosides - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Drugs | Derivation | Infections | Data bases | Variables | Body mass index | Databases | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Mathematical models | Teenagers | Pretreatment | Drug therapy | Drug dosages | Age | Antiretroviral drugs | Statistical analysis | Adjustment | Cut-off | Anemia | Data processing | Time measurement | Regression analysis | Ribonucleic acid--RNA | Patients | Antiretroviral therapy | CD4 antigen | Disease prevention | Sensitivity | Body mass | Cell number | Predictions | Adults
Journal Article
Journal of Medical Virology, ISSN 0146-6615, 02/2016, Volume 88, Issue 2, pp. 234 - 243
HIV drug resistance assessments and interpretations can be obtained from genotyping (GT), virtual phenotyping (VP) and laboratory‐based phenotyping (PT). We...
subtype | drug resistance | algorithm | Drug resistance | Algorithm | Subtype | VIRAL GENOTYPE | REVERSE-TRANSCRIPTASE | HIV-1-INFECTED PATIENTS | HUMAN-IMMUNODEFICIENCY-VIRUS | NAIVE | TREAT ASIA | VIROLOGY | COHORT | MUTATIONS | INTERPRETATION ALGORITHMS | PROTEASE | Anti-HIV Agents - pharmacology | Phenotype | Asia | HIV-1 - drug effects | HIV-1 - isolation & purification | HIV Infections - virology | Humans | Drug Resistance, Viral | Genotype | Genotyping Techniques - methods | HIV-1 - genetics | Microbial Sensitivity Tests - methods | Antiviral agents | Comparative analysis | HIV (Viruses) | HIV infection | Anti-HIV agents | Genotype & phenotype | Antiretroviral drugs | Virology
subtype | drug resistance | algorithm | Drug resistance | Algorithm | Subtype | VIRAL GENOTYPE | REVERSE-TRANSCRIPTASE | HIV-1-INFECTED PATIENTS | HUMAN-IMMUNODEFICIENCY-VIRUS | NAIVE | TREAT ASIA | VIROLOGY | COHORT | MUTATIONS | INTERPRETATION ALGORITHMS | PROTEASE | Anti-HIV Agents - pharmacology | Phenotype | Asia | HIV-1 - drug effects | HIV-1 - isolation & purification | HIV Infections - virology | Humans | Drug Resistance, Viral | Genotype | Genotyping Techniques - methods | HIV-1 - genetics | Microbial Sensitivity Tests - methods | Antiviral agents | Comparative analysis | HIV (Viruses) | HIV infection | Anti-HIV agents | Genotype & phenotype | Antiretroviral drugs | Virology
Journal Article
Journal fur Anasthesie und Intensivbehandlung, ISSN 0941-4223, 2017, Volume 2017-, Issue 2, pp. 12 - 14
Journal Article
International Journal of Tuberculosis and Lung Disease, ISSN 1027-3719, 11/2014, Volume 18, Issue 11, pp. 1327 - 1336
SETTING: Drug resistance threatens tuberculosis (TB) control, particularly among human immunodeficiency virus (HIV) infected persons. OBJECTIVE: To describe...
MDR-TB | ART programs | Asia | Africa | Latin America | INFECTIOUS DISEASES | RESPIRATORY SYSTEM | IMPLEMENTATION | TIME | DIAGNOSTICS | Directly Observed Therapy | Latin America - epidemiology | Africa - epidemiology | HIV Infections - epidemiology | Humans | Male | Antitubercular Agents - supply & distribution | Tuberculosis, Multidrug-Resistant - epidemiology | Tuberculosis, Multidrug-Resistant - diagnosis | Anti-HIV Agents - administration & dosage | Microbial Sensitivity Tests | Asia - epidemiology | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Surveys and Questionnaires | Developing Countries | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy
MDR-TB | ART programs | Asia | Africa | Latin America | INFECTIOUS DISEASES | RESPIRATORY SYSTEM | IMPLEMENTATION | TIME | DIAGNOSTICS | Directly Observed Therapy | Latin America - epidemiology | Africa - epidemiology | HIV Infections - epidemiology | Humans | Male | Antitubercular Agents - supply & distribution | Tuberculosis, Multidrug-Resistant - epidemiology | Tuberculosis, Multidrug-Resistant - diagnosis | Anti-HIV Agents - administration & dosage | Microbial Sensitivity Tests | Asia - epidemiology | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Surveys and Questionnaires | Developing Countries | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy
Journal Article